Detalhe da pesquisa
1.
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Oncologist
; 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38520745
2.
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need.
Int J Mol Sci
; 24(10)2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37240224
3.
Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Int J Mol Sci
; 24(12)2023 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37373267
4.
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Oncologist
; 27(2): 87-e115, 2022 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641222
5.
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.
Br J Cancer
; 125(12): 1602-1611, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34373568
6.
Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
Br J Clin Pharmacol
; 87(2): 527-541, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32495965
7.
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.
Int J Cancer
; 140(4): 930-937, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27859136
8.
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Adv Exp Med Biol
; 995: 97-125, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28321814
9.
Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.
Future Oncol
; 11(8): 1259-74, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25832881
10.
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma.
Dermatol Ther
; 33(6): e14417, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33068047
11.
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Oncologist
; 19(4): 344-5, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24674875
12.
Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient.
Hormones (Athens)
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421588
13.
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18.
Transl Lung Cancer Res
; 13(4): 875-884, 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38736500
14.
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?
Crit Rev Oncol Hematol
; 197: 104332, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38580184
15.
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC).
Crit Rev Oncol Hematol
; 195: 104228, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072173
16.
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
Future Oncol
; 9(3): 327-45, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23469969
17.
Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient.
Acta Biomed
; 94(S1): e2023070, 2023 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883626
18.
The role of biomarkers in stage III non-small cell lung cancer.
Expert Rev Respir Med
; 17(6): 469-480, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317885
19.
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
Transl Lung Cancer Res
; 12(2): 346-368, 2023 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895930
20.
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System.
Cancers (Basel)
; 15(6)2023 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36980737